INM News and Press, InMed Pharmaceuticals Inc.

2024-06-28 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips When does a growth stock become one of the top growth stocks to avoid? It sounds like the beginning of a riddle or a bad joke, but the answer is obvious – it’s when the st...

INM is advancing INM-089 targeting age-related macular degeneration and INM-901 targeting Alzheimer’s disease The company recently posted positive results for INM-089 demonstrating significant functional and pathological improvements in an AMD disease model Recent preclinical data for ...

2024-05-14 10:39:38 ET More on InMed Pharmaceuticals Historical earnings data for InMed Pharmaceuticals Financial information for InMed Pharmaceuticals Read the full article on Seeking Alpha For further details see: InMed Pharmaceuticals GAAP EPS of -$0.1...

Reported positive preclinical data in both its Alzheimer's and dry AMD programs Closed Fiscal Q3 with cash position of US$7.9 million Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharma...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD, a renowned leader in neurodegenerative disease, has joined its scientific advisory board (&...

Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the addition ...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signal...

Small molecule drug acting as a preferential signaling ligand for CB1/CB2 Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Vancouver, British Columbia--(Newsfile Corp. - April 16, 2024) - InMe...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting additional preclinical data demonstrating the positive effects of its INM-901 for the potential treatment of Alzheimer's di...

INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathway In Vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function Molecular analysis data further explains previously reported obser...